The Drug Opioid Surveillance Systems Missed

In forensic laboratories in Tennessee and Ohio, toxicologists began encountering something they could not immediately name. A compound kept appearing in overdose cases, structurally distinct from fentanyl, far more potent, and absent from standard screening panels. Existing opioid surveillance systems had no record of it. By the time it received a confirmed identity, N-propionitrile chlorphine, more commonly known as cychlorphine, authorities had already linked it to fatal overdoses on two continents.

The emergence of cychlorphine tells two stories at once. One is about a dangerous new drug. The other is about the limits of the systems we rely on to catch such threats early. For anyone concerned about where the synthetic opioid crisis is heading, the second story matters just as much.

A Compound Ten Times More Potent Than Fentanyl

Forensic officials in Tennessee describe cychlorphine as approximately ten times more potent than fentanyl, a drug that already sits around 100 times stronger than morphine. In at least one confirmed fatal case in Knox County, cychlorphine was the only substance found, present in femoral blood at roughly 0.5 nanograms. A nanogram is one-billionth of a gram.

The Knox County Regional Forensic Centre has reported 19 overdose deaths under investigation involving the compound, with 12 confirmed and seven awaiting laboratory confirmation. The Tennessee Bureau of Investigation recorded 11 seized drug submissions testing positive for cychlorphine in 2025, then nine more in the first 30 days of 2026. Ohio’s Bureau of Criminal Investigation identified it in seized materials alongside other high-potency synthetic opioids.

Across the Atlantic, British authorities linked cychlorphine to fatal overdose investigations in London. French and German laboratories confirmed its presence through advanced analysis. Germany scheduled the compound under its New Psychoactive Substances Act in late 2025, while a community drug-checking programme in Toronto flagged it in the Canadian supply.

Why Opioid Surveillance Systems Struggle to Keep Pace

Understanding why cychlorphine took time to surface in official data means looking closely at how opioid surveillance systems actually work and what they were originally built to do.

Most public overdose dashboards draw on death certificate data using federal ICD-10 classifications. These codes tend to group synthetic opioids into broad categories. A medical examiner may note a specific compound in the narrative section of a cause-of-death record, but that detail rarely reaches public-facing data. What gets counted depends on what gets coded.

The deeper challenge sits further upstream, inside the toxicology laboratory. Routine screening panels target known substances. When a newly engineered compound falls outside the panel’s reference library, it either returns an unidentified result or no signal at all. French researchers found that initial screening of cychlorphine samples flagged unidentified spectral peaks, simply because the compound was absent from existing libraries. Analysts needed high-resolution mass spectrometry and nuclear magnetic resonance testing to confirm what they had found. These are sophisticated techniques that sit well beyond standard forensic workflow.

That gap is not a minor technical footnote. It sits at the heart of the structural problem facing drug monitoring infrastructure today.

Opioid Surveillance Capacity Varies Sharply by Jurisdiction

Forensic capacity differs considerably between regions, and those differences can determine whether a new substance surfaces in official data at all.

Knox County’s regional forensic centre routinely submits femoral blood samples for expanded commercial toxicology analysis. That practice is precisely how cychlorphine came to light. Tennessee Bureau of Investigation crime labs, however, do not routinely screen for it in blood toxicology panels. Targeted testing is available on request, but only when there is specific cause to ask for it.

Arizona’s Department of Public Safety crime laboratory recently purchased a testing standard for cychlorphine and plans to begin validation procedures. Overdose death investigations there sit at county level, so whether expanded testing happens depends on the individual medical examiner. No statewide mandate currently exists.

These differences do not point to straightforward failure. They reflect how decentralised public health and forensic systems are structured. State and local opioid surveillance systems grew up primarily to classify causes of death and track broad trends. Rapid identification of novel engineered compounds was never part of their original design.

The Visibility Problem in Drug Monitoring Infrastructure

Policymakers reviewing drug monitoring data often miss a critical distinction: the difference between absence of evidence and evidence of absence.

When a jurisdiction reports no confirmed cases of a new synthetic opioid, it may genuinely be absent from the local supply. Equally, the drug could be present but undetectable because the toxicology panel does not cover it, because death investigation resources do not extend to expanded testing, or because coding practices bury substance-specific details inside narrative fields no dashboard captures.

The implications run deep. Policy responses and resources tend to follow confirmed case counts. If those counts reflect laboratory capacity more than actual drug prevalence, the communities most exposed may be exactly those least able to generate the data that would bring help. Fentanyl followed a similar trajectory. Standard screening panels in several US states missed it during its early spread because those panels were not calibrated to pick it up. Cychlorphine now appears to be repeating that pattern.

What Strengthening Drug Monitoring Infrastructure Actually Takes

Adapting drug monitoring infrastructure to catch emerging synthetic opioids in real time is achievable, but it demands genuine resource commitment.

Toxicology screening panels need regular updates to include newly identified compounds. Validated reference standards must exist commercially before laboratories can test for a substance, yet those standards often lag behind the drug’s first appearance in the supply. High-resolution equipment such as liquid chromatography-mass spectrometry systems carries significant procurement and maintenance costs. Trained analysts who can interpret complex spectral data and share findings across public health, law enforcement, and clinical networks are equally essential.

Data integration across agencies matters just as much as laboratory technology. Forensic labs, medical examiners, hospital emergency departments, and public health teams each capture a fragment of the picture. When those fragments stay siloed, the window for early intervention closes fast.

Community drug-checking programmes offer one promising complement to formal surveillance. In several cases, these harm reduction initiatives identified novel substances before they surfaced in any official forensic or mortality data. Toronto’s programme flagged cychlorphine in the local supply before official confirmation arrived. They are not a replacement for stronger opioid surveillance systems, but they function as a practical early warning layer that formal infrastructure currently cannot provide on its own.

A Structural Problem, Not Just a Chemical One

Cychlorphine may fade from the supply quickly, displaced by the next engineered compound before it spreads further. It may also persist. At this stage, no one can say with confidence which way it goes.

The broader pattern, however, is clear. The synthetic opioid market now moves faster than the opioid surveillance systems designed to track it. Novel high-potency compounds reach distribution networks before forensic panels are updated to detect them. Chemistry is running ahead of infrastructure.

Better intentions and harder work will not close that gap on their own. Closing it requires sustained investment in forensic capacity, regularly updated screening protocols, and integrated data systems. Without these, the most dangerous substances in the drug supply stay largely invisible to the very people responsible for responding to them.

Detection is not simply a matter of laboratory science. It is a matter of public health policy. And when detection fails, lives are what the failure costs.

Source: governing